We PRd the montifore group. We PRd our EIND group

We PRd the montifore group. We PRd our EIND group as a whole(https://www.cytodyn.com/newsroom/press-releases/detail/424/cytodyn-reports-strong-results-from-eind-covid-19-patients) and all you get is crickets. A pr for a single anecdotal patient is pretty worthless...now the old NP probably would have, but we're seeing a more reserved NP these days. Less PRs and more action. They didn't PR the conditional EUA request, we're finding out through canada's website that they are under review. They didn't PR the kickoff or fda blessing on the long haulers until we were half full. I think they are learning and I'm ok with it. I'm glad they didn't do a Philippines PR about that first patient because then they'd have to retract it. We need more meat PRs and less Mexico PRs. So I'm ok without having a single anecdotal patient not PRd, I prefer it. Besides the investor community will just point to out cd12 results.